1. The multicenter clinical trial of N+E combination therapy for second-stage sleeping sickness presented on behalf of G. Priotto and the NECT Study Team offers a better option than Eflornithine alone. In the comparative trial between the two arms, Eflornithine is given at 400mg/kg/day QIDX 14 days and the N+E combination of Nifurtimox at 15 mg/kg/day for 10 days and Eflornithine at 400mg/kg/day BID X 7 days. Thus the reduced dose of Eflornithine (reduced by half per day and for half the duration)can explain that while primary efficacy in one-sided non-inferiority test already show difference in cure rate in favor of N+E and the secondary efficacy indicators are also in favor of N+E, the major adverse events particularly fever, infection and neutropenia aside from selected clinical events (hypertension,diarrhea) are much lower with N+E. The presence of more seizure events with N+E has to be explained. , following on a previously reported terminated trial in nearby Omugo, where 17 patients received the combination under the same conditions. Eligible sequential late-stage patients received 400mg/kg/day eflornithine for 7 days plus 15mg/kg/day nifurtimox (20 mg/kg for children <15 years old) for 10 days. Efficacy (primary outcome)was monitored for 24 months post-discharge. Efficacy ranged from 90.3% to 100%; 5patients had major adverse events (neutropenia common, 9/31 patients)
This was a randomized open-label, active control, parallel clinical trialcompring three arms. Three drug combinations were randomily assigned to patients: melarsoprol-nifurtimox or M+N, melarsoproleflornithine or M+E, and nifurtimox-eflornithine or N+E. Dosages were uniform: Intravenous melarsoprol 1.8 mg/kg/day, daily for 10 days; IV eflornithine 400 mg/kg/day, every 6 hrs for 7 days; oral nifurtimox 15mg/kg /day(adults) or 20 mg/kg/day (children <15 years) given every 8 hrs for 10 days. Patients were followed up for 24 months.
Outcomes were cure rates and adverse events attributable to treatment. Result: Randomization performed in 54 patients before enrollment was suspended due to unacceptable toxicity in one of the three arms. Cure rates obtained with ITT analysis were M+N 44.4%, M+E 78.9%, and N+E 94.1%. Significantly higher with N+E (p=0.003) and M+E (p=0.045). Adverse events were less frequent and less severe with N+E, resulting in fewer treatment interruptions and no fatalities. N+E is a promising combination but no conclusion can be drawn from this interrupted study. (See larger current studies above) HAT develops in two stages, the first involving the hemolymphatic system, and the second, the neurological system. Left untreated, HAT is invariably fatal. There have been no therapeutic advances in more than 40 years. Stage 1 can be treated with pentamidine and suramin, but stage 2 can only be treated with melarsoprol, a toxic arsenic derivative that has a 2-12% incidence of fatal side-effects (encephalopathy). Eflornithine has never achieved widespread use because it is difficult to administer under field conditions. Nifurtimox has been used successfully in the treatment of American trypanosomiasis, or Chagas disease, but only in small studies or as a compassionate use treatment. There is little research and development for new drugs in this area: only one prodrug is in the clinical development phase, a pentamidine analog that offers hope for the replacement of injectable pentamidine with an orally administered drug. Current efforts appear to be focused on reevaluating older drugs. A course of treatment with melarsoprol for 10 days at 2.2 mg/kg/day is now in the multicenter evaluation phase. Orally administered eflornithine is also slated for reevaluation. In addition, studies of drug combinations are recommended to determine possible combined or synergistic effects and find ways to reduce toxicity. (Table 1; Mehlhorn and Schrevel 1995; Croft 1997; Hunter 1997; Wang 1997; Trouiller and Olliaro 1998) . All the available drugs have severe side-effects in humans and animals. Vaccination is not really an option, in view of the wide antigen variability. At present, there are several drug combinations in clinical trials: suramin/eflornithine, suramin/metronidazole, suramin/pentamidine, melarsoprol/pentamidine, melarsoprol/nifurtimox and nifurtimox/eflornithine. Some of these combinations were successful in treating resistant Trypanosoma brucei rhodesiense and/or T. b. gambiense infections (Keiser et al. 2001) . In leishmaniasis, the tendency is still to resort to the old antimony compounds, with their severe side effects. At present, miltefosine is in clinical phase and is the first oral drug against visceral leishmaniasis (Jha et al. 1999) . Two drugs are currently used against Chagas' disease, although these do not cure chronic effects. There is no prospect of novel drugs in this indication either (Pecoul et al. 1999; Morel 2000) . Kennedy, P. G. (2008) . "The continuing problem of human African trypanosomiasis (sleeping sickness Partners from the public and private sector are already engaged in joint initiatives to maintain the production of current drugs. This network should go further and be responsible for assigning selected teams to urgently needed research projects with funds provided by industry and governments. At the same time, on a long term basis, ambitious research programmes for new compounds must be supported to ensure the sustainable development of new drugs.
